Effect of an information leaflet on breast cancer screening participation: A cluster randomized controlled trial.

Breast neoplasms Diagnostic screening programs Early detection of Cancer Information leaflet Screening attendance Screening participation

Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
03 07 2021
Historique:
received: 03 02 2021
accepted: 16 06 2021
entrez: 4 7 2021
pubmed: 5 7 2021
medline: 6 8 2021
Statut: epublish

Résumé

To evaluate the impact of an information leaflet about the risk-benefit balance of breast cancer screening on women's participation. This cluster randomized controlled trial was conducted within a population-based breast cancer screening program and included women from the catchment areas of two hospitals in Barcelona, Spain. We evaluated women aged 50-69 years invited to screening between September 2019 and January 2020. The intervention group received an information leaflet on the benefits and harms of mammography screening. The control group received the usual invitation letter. The clusters consisted of the processing days of the invitation letter, assigned to the intervention with a simple random allocation scheme. We compared the participation rate at the individual level between groups, stratified by hospital and by per-protocol and intention-to-treat analyses. We included 11,119 women (137 clusters): 5416 in the intervention group (66 clusters) and 5703 in the control group (71 clusters). A total of 36% (1964/5393) of the women in the intervention group and 37% (2135/5694) of those in the control group attended screening, respectively. Overall, we found no differences in participation among groups (difference in participation - 1.1%; 95%CI; - 2.9 to 0.7%). In a hospital attending a population with a low socioeconomic status, attendance was lower in the intervention group (- 1.4, 95%CI: - 5.7% to - 0.03%). Overall participation in our program was unaffected by a new information leaflet on the risk-benefit balance of breast cancer screening. However, participation was lower in certain populations with lower socioeconomic status TRIAL REGISTRATION: Trial registration number ISRCTN13848929 .

Identifiants

pubmed: 34217258
doi: 10.1186/s12889-021-11360-0
pii: 10.1186/s12889-021-11360-0
pmc: PMC8254065
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1301

Références

J Med Screen. 2016 Sep;23(3):141-9
pubmed: 26566950
Prev Med. 2018 Jul;112:209-215
pubmed: 29678617
Cochrane Database Syst Rev. 2013 Jun 04;(6):CD001877
pubmed: 23737396
BMC Public Health. 2017 Apr 18;17(1):327
pubmed: 28420378
N Engl J Med. 2014 May 22;370(21):1965-7
pubmed: 24738641
JAMA. 2015 Oct 20;314(15):1615-34
pubmed: 26501537
Eur J Public Health. 2012 Jun;22(3):413-8
pubmed: 21746751
Ann Intern Med. 2016 Feb 16;164(4):279-96
pubmed: 26757170
Prev Med. 2019 Jun;123:130-137
pubmed: 30890352
Lancet. 2012 Nov 17;380(9855):1778-86
pubmed: 23117178
JAMA Intern Med. 2015 Feb;175(2):274-86
pubmed: 25531451
PLoS One. 2019 Mar 26;14(3):e0214057
pubmed: 30913217
Br J Cancer. 2014 Oct 28;111(9):1831-5
pubmed: 25167224
Ann Intern Med. 2020 Jan 7;172(1):46-56
pubmed: 31766052
J Gen Intern Med. 2017 Jul;32(7):803-812
pubmed: 28289963
Lancet. 2015 Apr 25;385(9978):1642-52
pubmed: 25701273
Dtsch Arztebl Int. 2015 Jan 30;112(5):61-8
pubmed: 25686383
Ann Intern Med. 2016 Feb 16;164(4):256-67
pubmed: 26756737
J Med Screen. 2021 Feb 25;:969141321993866
pubmed: 33632023
BMJ Open. 2017 Oct 6;7(10):e016894
pubmed: 28988175
J Med Screen. 2015 Dec;22(4):165-7
pubmed: 26018778

Auteurs

Jose Maria Montero-Moraga (JM)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.
Preventive Medicine and Public Health Training Unit PSMar-ASPB-UPF, Passeig Marítim 25-29, 08003, Barcelona, Spain.

Margarita Posso (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain. mposso@parcdesalutmar.cat.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain. mposso@parcdesalutmar.cat.

Marta Román (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.

Andrea Burón (A)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Maria Sala (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Xavier Castells (X)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Francesc Macià (F)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH